Rob
--- Rob <[EMAIL PROTECTED]> wrote:
Today, Bristol-Myers
Squibb Company (NYSE: BMY) announced that the Company has completed the
rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for dasatinib to treat chronic myelogenous leukemia (CML)
in chronic, accelerated or blast phases, as well as Philadelphia chromosome-
positive (Ph+) acute lymphoblastic leukemia (ALL).
The NDA seeks approval of dasatinib - an investigational multi-targeted
kinase inhibitor - to treat adult CML and Ph+ ALL patients with resistance or
intolerance to prior therapy.
Dasatinib was discovered and is being developed by scientists within
Bristol-Myers Squibb laboratories.
Posted by Rob to CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 12/29/2005 12:30:37 AM
Powered by NewOrleansEmail.Com http://neworleansemail.com
Powered by NewOrleansEmail.Com http://neworleansemail.com
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com
Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com
CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com
Post Message: [email protected]
Subscribe: [EMAIL PROTECTED]
Unsubscribe: [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED]
CML Group Web Site http://groups.yahoo.com/group/CML
SPONSORED LINKS
| Chronic myelogenous leukemia | Leukemia treatment | Cml |
YAHOO! GROUPS LINKS
- Visit your group "CML" on the web.
- To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
- Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
